RPL26

Across TCGA pan-cancer cohorts, RPL26 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of RPL26’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPL26 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL26 is over-expressed in tumor, although a few such as BRCA and UCEC show the opposite, repressed pattern.

KIRC, BRCA, and UCEC are the cancer types where RPL26 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL26 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.623	<.001	11	view →
BRCA	Female	II,III,IV	−0.652	<.001	8	view →
UCEC	All	All	−0.800	.004	6	view →
CHOL	All	All	+1.967	<.001	5	view →
KICH	Female	All	−1.410	<.001	4	view →
KIRP	All	II,III,IV	+0.651	.008	3	view →
PRAD	All	All	+0.303	.003	2	view →
THCA	All	II,III,IV	+0.272	.018	2	view →
LUSC	All	III,IV	−0.676	.048	1	view →
LIHC	All	II,III,IV	+0.553	.006	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

RPL26–KIRC

Open the KIRC breakdown →